Hesk: A spinoff is one of a few possibles.
Another is where Janssen licence a peptide/peptides for the clinic.
Still another could see other areas of Janssen build collaborations with PYC(refer to the following post):
http://hotcopper.com.au/post_threadview.asp?fid=1&tid=2155899&msgno=10152926#10152926.
I think any of those three possibles would make Phylogica glow.
peace: Seattle Genetics in the ADC space, is attracting bulk business from pharma but they haven't been acquired.
SoT
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
-0.035(2.46%) |
Mkt cap ! $810.7M | |||
| Open | High | Low | Value | Volume |
| $1.42 | $1.42 | $1.37 | $19.21K | 13.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 803 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 839 | 1 |
View Market Depth
| Last trade - 10.54am 23/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |